Driving to Reduce Socioeconomic Barriers to Latent Tuberculosis Infection Care: A Mobile Pediatric Treatment Program

Padma Swamy1, Cassandra Duran, Aditi Gupta

  • 1Department of Pediatrics, Baylor College of Medicine, Houston, Texas.

Insights

Preventing latent tuberculosis infection (LTBI) in high-risk children is crucial. A mobile clinic successfully implemented an LTBI treatment program, demonstrating effective community-based care for pediatric tuberculosis prevention.

Area of Science:

  • Public Health
  • Pediatric Infectious Diseases
  • Epidemiology

Background:

  • Tuberculosis (TB) poses significant global health challenges, with latent tuberculosis infection (LTBI) in children requiring effective prevention strategies.
  • Underresourced pediatric populations, particularly those who are foreign-born, are at higher risk for TB and often face barriers to accessing healthcare.
  • Mobile clinic programs offer a unique approach to reach underserved communities and address healthcare gaps.

Purpose of the Study:

  • To describe the implementation and outcomes of a latent tuberculosis infection (LTBI) treatment program within a pediatric mobile clinic setting.
  • To evaluate the effectiveness of a community-based approach in preventing tuberculosis among high-risk children.
  • To assess the feasibility of utilizing mobile clinics for LTBI screening and treatment in underresourced populations.

Main Methods:

  • A collaborative effort between the Texas Children's Mobile Clinic Program (TC-MCP) and TB experts established an LTBI treatment protocol.
  • Patients underwent tuberculin skin tests (TSTs), followed by interferon-γ release assays (IGRAs) for positive TSTs, and chest radiographs (CXRs) for IGRA-positive cases.
  • Children diagnosed with LTBI (positive IGRA, normal CXR) received 12 once-weekly doses of isoniazid/rifapentine (3HP) through outpatient mobile clinic visits.

Main Results:

  • Out of 785 patients screened, 38 (4.8%) had positive TSTs. A total of 19 patients were diagnosed with LTBI.
  • 18 out of 19 LTBI patients completed the 3HP therapy, with 83% attending at least two in-person mobile clinic visits.
  • The program demonstrated successful LTBI treatment completion within a community-based mobile clinic setting for a high-risk pediatric population.

Conclusions:

  • Mobile clinics can effectively extend the reach of healthcare services to underresourced children, successfully identifying and treating latent tuberculosis infection.
  • Community partnerships and a structured LTBI treatment program are vital for preventing the progression of tuberculosis in vulnerable pediatric populations.
  • This model highlights the potential of mobile health initiatives to bridge healthcare disparities and improve public health outcomes for infectious diseases.
Abstract

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
260
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
221
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
372
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
581
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
497
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
8